New Drugs on the Horizon for XXXX .

@entity1 @entity650 @entity310 @entity31 @entity16826 @entity8787 @entity62 @entity30 @entity4452
@entity310 antagonists have revolutionized the treatment of @entity8787 . Nevertheless, between 30 and 45% of @entity1 discontinue infliximab and other @entity310 antagonists over a 2- to 6-year period due to nonresponse, loss of response, or adverse events. Accordingly, the need for novel therapies grows each year. Recent studies have demonstrated the promise of new drugs with distinct modes of action for the treatment of @entity31 ( @entity31 ) and @entity30 ( @entity30 ). These include agents targeting leukocyte trafficking, therapies directed against IL-12/23 and Janus kinases (JAK), and antibodies against the classic inflammatory cytokine, @entity650 . The anti-a4-integrin antibody, natalizumab, was the first effective antitrafficking agent for @entity30 ; however, its use has been greatly limited by the risk of progressive multifocal @entity62 . Therefore, second-generation antitrafficking agents have focused on restricting leukocyte blockade to the intestine through mechanisms interfering with a4b7-integrin and its interaction with mucosal addressin cellular adhesion molecule 1. @entity4452 is a cytokine central to the adaptive immune responses that characterize @entity8787 . Ustekinumab, targeting the p40 subunit of IL-12 and @entity4452 , and the oral JAK inhibitor @entity16826 have proven to be effective in phase 2 trials in @entity30 and @entity31 , respectively. In addition, antibodies targeting the proinflammatory cytokine @entity650 are being studied in @entity30 . Each of the approaches described have promise as well as limitations, so it is likely that the search for novel agents in @entity8787 will continue.    2014 S. Karger AG, Basel.
